Logo

UCB’s Bimzelx (bimekizumab) Receives Health Canada’s Approval for the Treatment of Plaque Psoriasis

Share this
UCB’s Bimzelx (bimekizumab) Receives Health Canada’s Approval for the Treatment of Plaque Psoriasis

UCB’s Bimzelx (bimekizumab) Receives Health Canada’s Approval for the Treatment of Plaque Psoriasis

Shots:

  • The approval was based on P-III (BE VIVID/ BE READY/ BE SURE) studies evaluate Bimzelx vs PBO + ustekinumab & adalimumab in 1480 patients (315 patients were from Candana at 37 study sites) with PsO
  • The studies met its 1EPs & 2EPs i.e., improvement in measures of disease activity @16wk., improvements in psoriasis involving the scalp, nails, hands & feet, patients achieved superior levels of skin clearance as measured by 90% improvement in psoriasis area & severity index (PASI 90) & IGA response of clear or almost clear skin
  • Additionally, clinical responses were maintained ~@1yr. & patients achieved PASI 75 @4wk. Bimzelx is an IL-17A & IL-17F inhibitor

 Ref: Newswire.Ca | Image: Twitter

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions